Academic Medical Journal
ISSN 2412-8708 (Online)
About the Journal
The journal was founded in 1999
The journal «Family medicine» was founded in 1999 to inform medical society about achievements, problems and prospects of family medicine development in Ukraine. From the beginning the journal promotes family medicine, describes the activities of Ukraine Association of Family Medicine, publishes the reviews of the global formation and evidence of advantages of the primary medical care organization based on principals of family medicine in different countries. Due to the constant participation of the Shupyk National Medical Academy of Postgraduate Education in journal development and significant personal efforts of the first chief editor of the journal – prominent Ukrainian scientist and teacher prof. Grygorii Lysenko, - «Family Medicine» publishes wide spectrum of the original researches and recommendations in different fields from the leaders of medical science of Ukraine. In short time the journal become the leading edition, not only for family physicians but also for a wide circle of other medical specialists in Ukraine.
For practicing physicians
Obstetrics and gynecology
No. 1 (2021)
Dexibuprofen in the Practice of a Family Doctor
Pain is an unpleasant sensory and emotional sensation associated with tissue damage or described in terms of such damage. Pain of different localization is one of the most common symptoms in modern clinical practice and one of the most common reasons for seeking medical care at the outpatient stage. One of the most promising and effective pathogenetic means of protection of peripheral pain...
No. 1 (2021)
Plasma Hemostasis in Patients with Essential Hypertension and Non-alcoholic Fatty Liver Disease Under Conditions of Hypercholesterolemia and Concomitant Statin Therapy
In the modern scientific world, it has been proven that non-alcoholic fatty liver disease (NAFLD) is a marker of the risk of cardiovascular (CV) events, and therefore, attention and control of risk factors for CV diseases is important. Considering the prevalence of atherogenic dyslipidemias and their proven effect on the development of thrombotic CV complications in patients with NAFLD, it is...
No. 5-6 (2020)
USA Got the Rights to the Drug Arlevert®
Міжнародна компанія Castle Creek Pharmaceuticals (США), яка спеціалізується на розробці інноваційних засобів для лікування пацієнтів із патологією голови та шиї, дерматологічними захворюваннями, а також іншими клінічними станами, отримала від компанії Hennig Arzneimittel GmbH & Co. KG (Німеччина) ексклюзивні права на використання препарату Арлеверт® у Сполучених Штатах Америки.
Stay tuned! Subscribe now
Subscribe, so you never miss important information about achievements of medicine! We offer an annual subscription to our Journal